High dose AMBISOME on a fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: a Phase 3 randomised controlled non-Inferiority trial
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Amphotericin B liposomal (Primary) ; Amphotericin B; Fluconazole; Flucytosine
- Indications Cryptococcal meningitis
- Focus Therapeutic Use
- Acronyms AMBITION; Ambition-cm; Ambition-P3
- 06 Mar 2024 Results of study on stored plasma and CSF samples from the AMBITION trial evaluating whether CrAgSQ can predict outcomes presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 08 Mar 2022 The aim of this study is to find out whether a single high dose of L-AmB is as effective as the standard treatment in terms of preventing deaths from cryptococcal meningitis hence I have indexed trial focus as TU.
- 21 Jul 2021 Primary endpoint (All-cause mortality within the first 10 weeks after randomisation (non-inferiority)) has been met as per results presented at the 11th International AIDS Society Conference on HIV Science